BioPharmSignal logoBioPharmSignal

Biotech News

Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819

Fate Therapeutics (FATE)Fate TherapeuticsFDA / regulatory

FDA Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program supports the acceleration of manufacturing readiness for therapies with expedited clinical development timelines Current Regenerative Medicine Advanced Therapy (RMAT) designation and CDRP participation

Open original release

Related news

FATEFate Therapeutics2026-07-06 12:30 EST

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

FATEFate Therapeutics2026-06-04 12:30 EST

Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting

COGTCogent Biosciences2026-05-28 12:00 EST

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST

REPLReplimune Group2026-05-29 12:00 EST

Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA

ARGXArgenx2026-05-08 21:20 EST

argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG

BMYBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

INBXInhibrx2026-06-15 13:15 EST

Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma

GSKGSK plc2026-05-18 07:00 EST

GSK’s RSV vaccine, Arexvy, receives expanded approval in Japan for adults aged 18–59 at increased risk

BMYBMYBristol-Myers Squibb Company2026-05-08 10:59 EST

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults

KYMRKymera2026-07-07 11:00 EST

Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader

View all latest news

Fate Therapeutics

Fate Therapeutics is a cell-therapy company focused on engineered immune cells and off-the-shelf approaches to cancer and immune disease. Its strategy has long centered on platform ambition in cell therapy.

Recent company news

FATEFate Therapeutics2026-07-09 12:30 EST

Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate

FATEFate Therapeutics2026-07-06 12:30 EST

Fate Therapeutics to Present Preliminary Clinical Data of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Sclerosis at the ISSCR 2026 Annual Meeting

FATEFate Therapeutics2026-07-01 20:05 EST

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

FATEFate Therapeutics2026-06-15 12:30 EST

Fate Therapeutics Appoints Laura Hamill to Board of Directors

FATEFate Therapeutics2026-06-04 12:30 EST

Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting

Stock data

Close
2.43 USD
Market cap
299.56M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States